SI-BONE, Inc. (SIBN) News

SI-BONE, Inc. (SIBN): $33.76

0.16 (+0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SIBN News Items

SIBN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SIBN News Highlights

  • For SIBN, its 30 day story count is now at 4.
  • Over the past 10 days, the trend for SIBN's stories per day has been choppy and unclear. It has oscillated between 2 and 2.
  • The most mentioned tickers in articles about SIBN are AYTU, GENE and SI.

Latest SIBN News From Around the Web

Below are the latest news stories about SI-BONE Inc that investors may wish to consider to help them evaluate SIBN as an investment opportunity.

The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) ENDRA Life Sciences Inc. (NASDAQ: NDRA ) (announced a collaboration with Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ) for NASH studies) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Neos Therapeutics, Inc. (NASDAQ: NEOS ) (reacted to the shareholder meeting held to vote on the proposal to merge with Aytu BioScience, Inc. (NASDAQ: AYTU )) NuVasive, Inc. (NASDAQ: NUVA ) SI-BONE, Inc. (NASDAQ: SIBN ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) Varian Medical Systems, Inc. (NASDAQ: VAR ) Veric...

Benzinga | March 19, 2021

SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q4 2020 Results - Earnings Call Transcript

SI-BONE, Inc. (SIBN) Q4 2020 Earnings Conference Call March 8, 2021 4:30 P.M. ET Company Participants Matt Bacso - The Gilmartin Group Jeff Dunn - President and Chief Executive Officer Laura Francis - Chief Financial Officer and Chief Operating Officer Conference Call Participants David Lewis - Morgan Stanley Bob Hopkins...

SA Transcripts on Seeking Alpha | March 9, 2021

SI-BONE (SIBN) Investor Presentation - Slideshow

The following slide deck was published by SI-BONE, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | March 9, 2021

Earnings Outlook For SI-BONE

SI-BONE (NASDAQ:SIBN) releases its next round of earnings this Monday, March 08. Get the latest predictions in Benzinga's essential guide to the …

Benzinga | March 5, 2021

These 3 “Strong Buy” Stocks Are Top Picks for 2021, Say Analysts

Some traditions are too time-honored to shirk, and on Wall Street, the annual ‘top picks’ are one. Usually made at the very end or very beginning of a year, the Street’s analysts publish reviews on the stocks they believe will show the best performance in coming months – their top picks. The analysts have been analyzing each stock carefully, looking at its past and current performance, its trends on a variety of time frames, management’s plans – they take everything into account. Their recommendations provide valuable direction for building a resilient portfolio in the new year.

Michael Marcus on TipRanks | January 17, 2021

SI-BONE Announces Senior Leadership Changes and Record Quarterly Revenue

Laura Francis to Become Chief Executive Officer; Jeff Dunn to Become Executive Chairman;  and Tony Recupero to Become President.SANTA CLARA, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE” or the “Company”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors. Laura Francis currently serves as SI-BONE’s Chief Financial Officer and Chief Operating Officer. As CEO, Laura Francis will succeed Jeff Dunn, who will remain with the Company as Executive Chairman. Tony Recupero, one of the industry’s leading executives who has been with the company f...

Yahoo | January 7, 2021

SI-BONE, Inc. Announces that Updated ISASS Policy and Guidelines on MIS SI Joint Fusion Support Only Lateral Transiliac MIS Procedures

SANTA CLARA, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that the International Society for the Advancement of Spine Surgery (ISASS) published an early view of its updated Policy on MIS Sacroiliac Joint Fusion (For Chronic Sacroiliac Joint Pain) in the December 2020 issue of the International Journal of Spine Surgery (https://www.ijssurgery.com). The policy and guidelines remain supportive of continued adoption of MIS SI joint fusion procedures by the clinician and payor communities, limited to procedures using a lateral transiliac approach, which includes the iFuse Procedure™. While the ISASS policy does not endorse any sp...

Yahoo | January 4, 2021

SI-BONE Announces Pricing of Public Offering of Common Stock

SANTA CLARA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced the pricing of its underwritten public offering of 3,190,053 shares of its common stock at a price to the public of $22.00 per share. Of the shares of common stock being offered, 3,000,000 shares are being offered by SI-BONE and 190,053 shares are being offered by a selling stockholder. Gross proceeds to SI-BONE from the offering are expected to be $66.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  SI-BONE will not receive any proceeds from the sale of the shares of comm...

Yahoo | October 15, 2020

SI-BONE Announces Launch of Public Offering of Common Stock

SANTA CLARA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced that it has commenced an underwritten public offering of 3,190,053 shares of its common stock. In addition, SI-BONE expects to grant the underwriters a 30-day option to purchase up to an additional 478,507 shares of common stock on the same terms and conditions. Of the shares of common stock being offered, 3,000,000 shares are being offered by SI-BONE and 190,053 shares are being offered by a selling stockholder. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering m...

Yahoo | October 14, 2020

SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance

SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the three and nine months ended September 30, 2020. Preliminary and unaudited revenue for the three months ended September 30, 2020 is expected to be in the range of $20.1-$20.4 million, reflecting growth of 24%-26% compared to the prior year period. U.S. revenue is expected to be in the range of $18.7-$18.9 million, reflecting growth of 26%-27% compared to the prior year period. International revenue is expected to be in the range of $1.4-$1.5 million.Preliminary and unaudited revenue for the nine months ended September 30, 2020 is expected to be in the r...

Yahoo | October 8, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7429 seconds.